Posted by Michael Wonder on 10 Nov 2023
Mirati Therapeutics receives positive opinion from CHMP for Krazati (adagrasib) as a targeted treatment option for patients with advanced non-small cell lung cancer with a KRAS G12C mutation following a re-examination procedure
10 November 2023 - Mirati Therapeutics today announced that following a re-examination procedure, the Company has received a positive opinion from the EMA's CHMP on Krazati (adagrasib) as a targeted treatment option for adult patients with KRAS G12C -mutated advanced non-small cell lung cancer and disease progression after at least one prior systemic therapy.
"Today's positive opinion from the CHMP for Krazati marks an important step on the path to providing access to a potentially best-in-class therapeutic option to patients living with this difficult-to-treat disease," Alan Sandler, M.D., chief medical officer, Mirati Therapeutics, Inc. "We look forward to approval from the European Commission and the opportunity to positively impact the lives of eligible patients living in the European Union."
